Obstetrics, gynecology and reproductive medicine guidelines

Female genital neoplasms

PubMed Free Full Text

Ovarian cancer: treatment

Australia

• National Breast and Ovarian Cancer Centre
  • Neoadjuvant chemotherapy in ovarian cancer: a systematic review [2009]

Canada

• Cancer Care Ontario
  • Optimal chemotherapy for recurrent ovarian cancer [2011]
  • The role of intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer : a clinical practice guideline [2006]
  • First-line Chemotherapy for Postoperative Patients with Stage II, III or IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [2004]
  • Adjuvant care for stage 1 ovarian cancer [2004]
  • Chemotherapy for Recurrent Epithelial Ovarian Cancer Previously Treated with Platinum [2003]

• Society of Gynecologic Oncologists of Canada
  • Use of Systemic Therapy in Women with Recurrent Ovarian Cancer - Development of a national clinical practice guideline [2007]
  • Intraperitoneal Chemotherapy for Patients with Advanced Ovarian Cancer: A Review of the Evidence and Standards for the Delivery of Care [2007]

• Society of Obstetricians and Gynaecologists of Canada
  • Management of Low Malignant Potential Tumour of the Ovary [2000]

International

• Annals of Oncology
  • Integration of new or experimental treatment options and new approaches to clinical trials [2005]
  • Clinical trials in ovarian carcinoma: study methodology [2005]
  • Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens [2005]

• Cochrane Library
  • Topotecan for ovarian cancer
  • Tamoxifen for relapse of ovarian cancer
  • Palliative surgery versus medical management for bowel obstruction in ovarian cancer
  • Optimal primary surgical treatment for advanced epithelial ovarian cancer
  • Maintenance chemotherapy for ovarian cancer
  • Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer
  • Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
  • Interventions for the treatment of borderline ovarian tumours
  • Interval debulking surgery for advanced epithelial ovarian cancer
  • DNA-repair pathway inhibitors for the treatment of ovarian cancer
  • Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer
  • Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer
  • Chemotherapy for advanced ovarian cancer
  • Antigen-specific active immunotherapy for ovarian cancer
  • Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer

• Gynecologic Oncology Group
  • CA-125 Change Following Chemotherapy in Prediction of Treatment Outcome among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers: A Gynecologic Oncology Group Study [2009]

United Kingdom

• Health Technology Assessment
  • Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation [2006]

• National Institute for Health and Clinical Excellence
  • Ovarian cancer (relapsed) - trabectedin [2011]
  • Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) [2005]
  • Ovarian Cancer - paclitaxel [2003]

• Royal College of Obstetricians and Gynaecologists
  • Ovarian Cancer, Optimum Surgery in Advanced-stage [2011]
  • Granulosa cell tumour - query bank [2010]
  • Targeted therapies for the management of ovarian cancer [2009]

United States of America

• National Cancer Institute
  • Ovarian Cancer Trial Results

• Society of Gynecologic Oncologists
  • Position Statement on the Use of Intraperitoneal (IP) Chemotherapy for Ovarian Cancer [2006]

Articles in journals

• Annals of Oncology
  • Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer [2007]
  • The role of surgery in advanced and recurrent ovarian cancer [2006]
  • New targets and non-cytotoxics in ovarian cancer [2006]

• Discovery Medicine
  • Treatment of Ovarian Cancer by Monoclonal Antibodies [2010]
  • Adoptive T Cell Immunotherapy Strategies for the Treatment of Patients with Ovarian Cancer [2010]

• Expert Opinion on Biological Therapy
  • Cellular immunotherapy for ovarian cancer [2009]

• Future Oncology
  • Nanomolecular targeting of dendritic cells for ovarian cancer therapy [2009]

• Gynecologic Oncology
  • Epigenetic Therapies for Chemoresensitization of Epithelial Ovarian Cancer [2009]

• Journal of Hematology & Oncology
  • Ovarian cancer immunotherapy: opportunities, progresses and challenges [2010]

• Oncologist
  • The Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer [2009]
  • The Future of Targeted Therapies in Ovarian Cancer [2009]

• Reproductive Biology and Endocrinology
  • Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer [2003]
  • Chemoresistance in human ovarian cancer: the role of apoptotic regulators [2003]

{Related topics}

• Guidelines
  • Ovarian cancer